short engagement, selective CDK9 kinase inh.
IV treatment in Ph. I for RR-heme cancers
shortened t1/2 from prior preclin. candidate
J. Med. Chem., Dec. 11, 2020
AstraZeneca, Cambridge, UK / Boston, MA
AZD4573
1 min read
AstraZeneca selective CDK9 kinase inhibitor
Search By Structure
- OI338
- PF07059013
- AZD0364
- PF-06843195
- TP0586352
- AZD4573
- “compound 42”
- “compound 12”
- BMS-986202
- pamiparib
- linrodostat
- SAR439859
- ACT-1004-1239
- “compound 1”
Molecules of the Month
2023
2022
2021
2020